BIOMARIN PHARMACEUTICAL INC business relationships
Companies named in BIOMARIN PHARMACEUTICAL INC’s 10-K filed 2026-02-26, and public companies whose annual reports name BIOMARIN PHARMACEUTICAL INC. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.6 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in BIOMARIN PHARMACEUTICAL INC’s annual report 4
“We evaluated the Company's ability to estimate the variable consideration by comparing historical estimates of sales volume and price per vial to actual current-period sales volume and price per vial of product sold by Sanofi.” SEC filing
“Sanofi is our sole customer for ALDURAZYME and is responsible for distributing, marketing, and selling ALDURAZYME to third parties.” SEC filing
“We developed ALDURAZYME through collaboration with Sanofi.” SEC filing
“Sanofi has the exclusive right to distribute, market and sell ALDURAZYME globally and is required to purchase its requirements exclusively from us.” SEC filing
Companies whose annual reports name BIOMARIN PHARMACEUTICAL INC 3
“In September 2024, the Company entered into a Collaboration and License Agreement (the "BioMarin Agreement") with BioMarin Pharmaceutical Inc. ("BioMarin").” SEC filing
“License Agreement with BioMarin Pharmaceutical, Inc.” SEC filing
“The in-licensed rights primarily relate to agreements with BioMarin Pharmaceutical, Inc. ("BioMarin"), the University of Western Australia ("UWA"), the Research Institute at Nationwide Children's Hospital ("Nationwide") and Parent Project Muscular Dystrophy ("PPMD").” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.